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Abstract 26 
Purpose: Management of ureteral stones remains controversial. To determine whether 27 
optimizing extracorporeal shock wave lithotripsy (ESWL) delivery rates improves treatment of 28 
solitary ureteral stones, we compared outcomes of two SW delivery rates in a prospective, 29 
randomized trial. 30 
Materials and Methods: From July 2010 to October 2012, 254 consecutive patients were 31 
randomized to undergo ESWL at SW delivery rates of either 60 pulses (n=130) or 90 pulses 32 
(n=124) per min. The primary endpoint was stone-free rate at 3-month follow-up. Secondary 33 
endpoints included stone disintegration, treatment time, complications, and the rate of secondary 34 
treatments. Descriptive statistics were used to compare endpoints between the two groups. 35 
Adjusted odds ratios and 95% confidence intervals were calculated to assess predictors of 36 
success. 37 
Results: The stone-free rate at 3 months was significantly higher in patients who underwent 38 
ESWL at a SW delivery rate of 90 pulses per min than in those receiving 60 pulses (91% vs. 39 
80%, p=0.01). Patients with proximal and mid-ureter stones, but not those with distal ureter 40 
stones, accounted for the observed difference (100% vs. 83%; p=0.005; 96% vs. 73%, p=0.03; 41 
and 81% vs. 80%, p=0.9, respectively). Treatment time, complications, and the rate of secondary 42 
treatments were comparable between the two groups. In multivariable analysis, SW delivery rate 43 
of 90 pulses per min, proximal stone location, stone density, stone size and the absence of an 44 
indwelling JJ stent were independent predictors of success.  45 
Conclusions: Optimization of ESWL delivery rates can achieve excellent results for ureteral 46 
stones. 47 
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Introduction 48 
Extracorporeal shock-wave lithotripsy (ESWL) for stone disease using the Dornier HM-3 49 
lithotripter (Dornier MedTech, Wessling, Germany) was introduced more than 30 years ago (1). 50 
Since then improvements in shock-wave (SW) technology have been minimal, and current 51 
devices fail to match the efficacy of the Dornier HM-3 (2–4). During this time endourological 52 
procedures, which offer the possibility of one-time complete clearance, have become 53 
increasingly popular. Nevertheless, ESWL, along with ureterorenoscopy (URS), remains an 54 
accepted treatment for urolithiasis, including stones located in the ureter (5). In fact, depending 55 
on stone location and size, ESWL may be the better option, with the advantage of being a 56 
noninvasive procedure.  57 
Recent research has focused on finding ways to make ESWL more effective. Optimizing 58 
lithotripter setting parameters, notably SW delivery rates, has been shown to possibly improve 59 
treatment outcomes (6). Several studies evaluated the impact of SW delivery rates on stone 60 
clearance in kidney stones comparing SW delivery rates of 60 versus 120 pulses per min (7–11). 61 
Most of these studies (7–10) reported better success rates in kidney stones with the lower SW 62 
delivery rate of 60 pulses per min. A recent meta-analysis of randomized trials found that SW 63 
delivery rates of 60 and 90 pulses per minute yield better results than higher frequencies, but 64 
suggested that 90 pulses per minute may be the optimal SW delivery rate because of the shorter 65 
treatment duration (12). To extend these observations in the setting of ureteral stone disease, and 66 
especially since data on the impact of SW delivery rates on ESWL efficacy in ureteral stones are 67 
sparse and inconsistent (10,13,14), we conducted a large prospective, randomized trial 68 
comparing ESWL efficacy at 60 versus 90 pulses per min using the modified Dornier HM-3 for 69 
solitary ureteral stones. 70 
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Material and Methods 71 
A total of 260 patients (207 males and 53 females) ≥ 18 years of age with previously untreated, 72 
unilateral radiopaque ureteral stones requiring elective or emergency ESWL were recruited from 73 
July 2010 to October 2012 at our department. Patients in whom it was technically impossible to 74 
localize the stone (e.g. due to patient obesity) on the day of intervention (n=4), or who refused to 75 
participate (n=2) were excluded. Upon entry into the study, each patient was randomly assigned 76 
by a computer-based program without stratification to receive ESWL at a SW delivery rate of 60 77 
pulses (group A, n=130) or 90 pulses (group B, n=124) per min. Fourteen of these patients were 78 
excluded from analysis due to loss to follow-up (Group A: n=3; group B: n=11; Fig.1). Patient 79 
baseline and stone characteristics were comparable between the two groups (Table 1). The study 80 
protocol was approved by the Ethics Committee of the Canton Bern, Switzerland (protocol 81 
number 089/10). All patients provided informed written consent to participate in the study prior 82 
to randomization.  83 
 84 
a) Preoperative assessment  85 
Preoperative 12-lead ECGs were performed on all patients with 2 or more cardiovascular 86 
risk factors (arterial hypertension, hypercholesterolemia, history of smoking, body mass index 87 
[BMI] ≥ 30 kg/m², diabetes), history of subarachnoidal bleeding, or systemic disease with 88 
potential cardiac involvement. ECGs were interpreted by a cardiologist and reviewed by an 89 
anesthesiologist. None of the patients had active coronary heart disease, a history of cardiac 90 
surgery, severe pretreatment cardiac arrhythmias, or other significant cardiac symptoms or signs. 91 
Had there been such patients, they would have been excluded from the study to ensure patient 92 
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safety from a cardiovascular standpoint as the ESWL treatment included potential 93 
pharmacological manipulation to regulate heart rate (see below). 94 
b) ESWL protocol  95 
The technical features of the modified Dornier HM3 are described elsewhere (2). The 96 
Dornier HM-3 was operated by the same technician with more than 25 years of experience at the 97 
start of the study, under the supervision and guidance of a specially-trained resident and a senior 98 
staff member (2). All ESWL treatments were given under anesthesia (general or regional) to 99 
eliminate pain as a limiting factor and to keep respiratory movements regular (Table 1). SW 100 
delivery was ECG gated. If necessary, patients underwent pharmacological manipulation with 101 
atropine/hyoscine butylbromide or esmolol to maintain the required heart rate/SW delivery rate.  102 
SW voltage began with a series of 500 SWs at 19 kV, thereafter it was increased in 1-kV 103 
steps every 300 SWs to a maximum of 21kV to 22kV if fluoroscopic controls showed 104 
insufficient fragmentation. In case of stone disintegration, voltage was progressively decreased 105 
to prevent unnecessary trauma (9). A maximum of 2500 SWs for proximal ureteral stones and 106 
3000 SWs for ureteral stones off the kidney were administered. ESWL was terminated prior to 107 
reaching the maximum number of SWs upon documentation of complete fragmentation on x-ray 108 
snapshots. All patients were given α-blockers after ESWL. 109 
c) Outcome measures 110 
Kidney, ureter and bladder x-rays and renal ultrasound were obtained 1 day and 3 months after 111 
ESWL. Additional imaging (x-ray, renal ultrasound, computed tomography and/or excretory 112 
urography) was only used if deemed necessary in order to reduce exposure to ionizing radiation 113 
and to limit costs. Stone disintegration was classified as no fragments, fragments <2 mm, 114 
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fragments 2mm to 5 mm, and fragments >5 mm. Complications and secondary treatments were 115 
prospectively evaluated. Stone composition was documented if available. The investigators who 116 
assessed clinical outcomes were blinded to patient treatment information.  117 
d) Study endpoints and statistical analyses 118 
 The primary study endpoint was success rate 3 months following ESWL, defined as the 119 
stone-free rate after a single ESWL session, i.e. without the need for secondary treatment. 120 
Secondary endpoints were stone disintegration, treatment time, complications (Clavien-Dindo 121 
classification) including kidney hematoma, and the rate of secondary treatments, which included 122 
re-ESWL, placement of a JJ stent, percutaneous nephrolithotomy, and URS. 123 
Based on the assumption that the overall drop-out rate would be 10% and that the stone-124 
free rate at 3 months would be 90% after treatment with 60 SWs per min and 78% after 90 SWs 125 
per min, a sample size of 254 patients (n=127 per group) was needed to obtain a statistical power 126 
of 80% (β=0.2) using a two-sided test at the significance level of 5% (α=0.05). Categorical and 127 
continuous variables were compared using the χ2 and Mann-Whitney U tests, respectively. A 128 
two-tailed p value <0.05 was considered significant. Adjusted odds ratios (OR) and 95% 129 
confidence intervals (CI) were calculated in a logistic regression model to assess predictors of 130 
treatment success. Confounders with a univariate significance level of ≤ 10% (α ≤ 0.1) were 131 
included in multivariable analyses (SW delivery rate, stone location, stone density measured in 132 
Hounsfield units, stone size, and presence of an indwelling JJ stent). Statistics were performed 133 
using SAS 9.1 software (SAS Institute Inc., Cary, NC).134 
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Results  135 
The stone-free rate at 3-month follow-up was significantly higher in patients who 136 
underwent ESWL at a SW delivery rate of 90 pulses per min than at 60 pulses per min (103/113 137 
[91%] vs. 101/127 patients [80%], p=0.01). Patients with proximal and mid-ureter stones, but not 138 
those with distal ureter stones, accounted for the observed difference (Table 2). Similarly, stone 139 
disintegration was better at 90 pulses per min (p=0.04). Treatment time and complications were 140 
comparable between the two groups (Table 2). Sixteen of 127 (13%) patients in group A (60 SW 141 
per min) and 7 of 113 (6%) patients in group B (90 SW per min) required a secondary treatment 142 
(p=0.06; Table 2). Stone analysis was available in 75 of 127 (59%) patients in group A and 81 of 143 
113 (72%) patients in group B. The distribution of stone composition in these patients did not 144 
differ between the two groups (p = 0.09; Fig. 2).  145 
Multivariable logistic regression analysis showed an association between treatment 146 
success and SW delivery rate in favor of a frequency of 90 pulses per min (OR: 0.43, 95% CI 147 
0.19-0.96, p=0.02; Table 3). Other predictors of success were proximal stone location, lower 148 
stone density, smaller stone size, and the absence of an indwelling JJ stent. Because patient age, 149 
gender, and BMI were not associated with treatment success in univariate analysis (p > 0.1), 150 
these variables were not included in the logistic regression model. 151 
152 
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Discussion 153 
Classical variables that determine ESWL success rates include stone burden, stone 154 
composition and location, level of operator experience, and the type of lithotripter used. The last 155 
decade has seen an increasing interest in improving success rates by manipulating lithotripter 156 
setting parameters, which include maximal voltage, voltage escalation, and SW delivery rate (6). 157 
In the present prospective, randomized study using the “Rolls-Royce” among lithotripters, the 158 
Dornier HM-3 to treat ureteral stones, we show that SW delivery rates of 90 pulses per min are 159 
associated with significantly better treatment outcomes than SW delivery rates of 60 pulses per 160 
min. Rates of 90 pulses per min delivered an overall stone-free rate of 91% and, for mid-ureter 161 
and proximal ureteral stones, stone-free rates of >95%. These findings are relevant in the context 162 
of the declining popularity of ESWL for ureteral stones, indicating that optimizing the SW 163 
delivery rate can achieve excellent outcomes even for mid-ureter and proximal ureteral stones.   164 
 As newer lithotripters emerged, an increased interest in shorter ESWL treatment times 165 
led to several randomized trials designed to evaluate the potential role of SW delivery rates. 166 
Based on manufacturers’ recommended SW delivery rates in second- and third-generation 167 
devices, the majority of these studies compared frequencies of 60 pulses per min versus 120 168 
pulses (6–11,13). Although not without limitations, such as lack of control over the number of 169 
ESWL sessions (10) or overall low success rates regardless of SW delivery rate (7,8,13), the 170 
majority of these studies reported higher success rates at a SW delivery rate of 60 pulses per min. 171 
Honey et al specifically investigated upper ureteral stones only and found improved outcomes at 172 
a SW delivery rate of 60 versus 120 pulses per min (13), with stone-free rates at 3-month follow-173 
up of 64.9% and 48.8%, respectively. Conversely, Robert et al reported success rates of 65% and 174 
89% for lower ureteral stones (p = 0.04) at SW delivery rates of 60 and 240 pulses per min, 175 
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respectively (14). In the present study, we chose to evaluate the modified Dornier HM-3 because 176 
it remains the gold standard against which treatment outcomes with other lithotripters are 177 
compared. In addition, we included only patients with ureteral stones. Indeed, while ESWL 178 
efficacy for renal stones is well documented (2–4), management of ureteral stones remains 179 
controversial, as ESWL and primary URS represent equally popular treatment options (5). 180 
Although we achieved acceptable results at the lower SW delivery rate of 60 pulses per min, 181 
more than 9 of 10 patients receiving 90 pulses per min were stone-free at 3 months. Our results 182 
compare favorably with those of studies evaluating new-generation lithotripters, in which stone-183 
free rates after a single ESWL session for ureteral stones ranged from 57% to 82% (13–15). In 184 
recent years these mixed results, combined with advances in endourological techniques, have 185 
prompted many urologists to turn to primary URS for ureteral stone removal.  186 
The reasons for the superior ESWL efficacy at 90 pulses per min may be related to 187 
favorable cavitation bubble dynamics. Shock waves create pressure changes that lead to bubble 188 
formation (16). When these bubbles collapse at the stone surface, they release high-energy waves 189 
that induce stone fragmentation (17). An increased SW delivery rate leads to increased 190 
production of cavitation bubbles at the stone surface (16), potentially leading to enhanced 191 
fragmentation. On the other hand, residual bubbles that are not reflected on the stone and that do 192 
not dissipate before the arrival of the next SW may act as a barrier that attenuates SW energy 193 
transmission (16). It has also been postulated that stone particles that persist between SWs can 194 
serve as cavitation nuclei. The resulting bubble growth may absorb part of the energy from the 195 
negative-pressure phase of the SW, ultimately reducing stone breakage (18). These two theories 196 
have been advanced to explain why low success rates were observed at SW delivery rates of 120 197 
pulses per min (16,18). Therefore, a SW delivery rate of 90 pulses per min may provide the 198 
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optimal balance by supporting favorable cluster bubble dynamics on the stone surface while 199 
allowing enough time for the barrier of residual bubbles or stone particles to dissipate. A SW 200 
delivery rate of 90 pulses per min may also enhance stone fatigue, which is another postulated 201 
mechanism of stone breakage (19,20).  202 
 Among the secondary findings of our study, stone location was shown to be a predictive 203 
factor for treatment success, success being significantly associated with proximal ureteral stones 204 
as reported previously (15,21). Reduced stone fragmentation in the lower ureter may reflect 205 
attenuation of SW energy by the organic environment surrounding the stone, i.e. abdominal gas 206 
interposition and/or an energy absorptive effect of the bony pelvis and muscle mass of the 207 
buttocks (19). Moreover, fluoroscopic focusing in the pelvis may be more difficult due to fecal 208 
air and content and/or projection in front of the sacroiliac joint. Another possible explanation is 209 
the smaller fluid interface surrounding the stone in the lower ureter (22). Despite this, we and 210 
others have previously reported stone-free rates >90% for distal ureteral calculi (23,24), and, in 211 
the current study, 82 of 102 patients (80.4%) with distal ureteral stones were stone-free 3 months 212 
after ESWL. Therefore, stone location in the lower ureter does not necessarily preclude the use 213 
of ESWL as a primary treatment option.  214 
 We also found that the presence of an indwelling JJ stent reduced the chance of treatment 215 
success. These findings echo those of previous studies (15,21). The magnitude of SW 216 
transmission and reflection travelling to the stone depends on the acoustic impedance of the 217 
intervening structures (19). Thus, lower success rates in stented patients may result from partial 218 
SW absorption by the ureteral stent. It has also been shown that stents impair ureteric peristalsis 219 
and/or trap larger stone fragments, thereby reducing stone clearance (25). Nevertheless, JJ stents 220 
are still needed for patients in the emergency setting or receiving treatment outside referral 221 
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centers, where lithotripters are not readily available. Other predictors of outcome were stone size 222 
and density, which are generally accepted factors affecting ESWL treatment outcomes 223 
(8,10,15,21,26,27). BMI was not associated with outcomes in our patients. This finding accords 224 
with a recent study that found BMI and skin-to-stone distance to have no effect on ESWL 225 
efficacy with the Dornier HM-3 (28). Regarding newer lithotripters and BMI, some authors 226 
report an association between BMI and treatment outcomes (21,26) and some do not (7,13). 227 
The main limitation of our study is that all patients were treated with the modified 228 
Dornier HM-3. It is unknown, therefore, whether our results can be generalized to the current 229 
generation of electromagnetic or piezoelectric lithotripters. The optimal SW delivery rate may 230 
vary depending on the type of device 231 
232 
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Conclusions 233 
Excellent outcomes of ESWL for ureteral stones can be achieved by optimizing the SW 234 
delivery rate, especially for stones located more proximally. Our results should encourage other 235 
high-volume centers to design similar studies to determine optimal treatment parameters for the 236 
most commonly used lithotripters.  237 
238 
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 Table 1 - Patient and stone characteristics 
 
Group A 
(60 SWs per min) 
n=127 
 Group B 
(90 SWs per min) 
n=113 
 p-value 
Median age (years; range) 48 (18-84)  49 (19-84) 0.9 1 
 
Median BMI (range) 25.6 (17-61.7)  26.6 (17.9-36.5) 0.2 1 
Gender, no (%) 
   
0.3 2 
    male 103 (81)  86 (76) 
 
    female 24 (19)  27 (24) 
 
Anesthesia, no (%) 
   
0.1 2 
     PDA 52 (41)  46 (41) 
 
     GA 12 (9)  19 (17) 
 
     Spinal single shot 63 (50)  48 (42) 
 
JJ in place, no (%)  
   
0.4 2 
     no 96 (76)  91 (81) 
 
     yes 31 (24)  22 (19) 
 
Stone size, no (%) 
   
0.3 2 
     < 5 mm 37 (29)  39 (35) 
 
     5 – 10 mm 65 (51)  60 (53) 
 
     10 – 20 mm 22 (17)  14 (12) 
 
     > 20 mm 3 (2)  0 (0) 
 
Stone location, no (%) 
   
0.7 2 
     proximal ureter 42 (33)  43 (38) 
 
     midureter 30 (24)  23 (20) 
 
     distal ureter 55 (43)  47 (42) 
 
Stone density, no (%) 
   
0.2 2 
     < 500 HU 9 (7)  8 (7) 
 
     500 - 1000 HU 83 (65)  81 (72) 
 
     > 1000 HU 35 (28)  24 (21) 
 
Mean no. of SW applied (SD) 2381 (745) 
 
2401 (550) 0.5 1 
 Abbreviations:   
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 Table 2 - Outcomes 
 
Group A 
(60 SWs per min) 
n=127 
 Group B 
(90 SWs per min) 
n=113 
 p-value 
Stone free rate at 3 mos, no (%) 
 
    Proximal ureter 
 
    Midureter 
 
    Distal ureter 
101 (80) 
35 (83) 
22 (73) 
44 (80) 
 
 103 (91) 
43 (100) 
22 (96) 
38 (81) 
0.01 1 
 
0.0051 
 
0.03 1 
 
0.91 
 
 
Stone disintegration, no (%) 
   
0.04 1 
    No fragments 100 (79)  103 (91)  
    0-2 mm 
 
12 (9)  4 (4) 
 
    2-5 mm 6 (5)  3 (3) 
 
    > 5 mm 9 (7)  3 (3) 
 
Treatment time, min, mean (SD) 36.4 (13.6)  35.3 (9.4) 0.9 2 
Complications, no (%) 13 (10)  17 (15) 0.2 1 
     Grade 1 6 (5)  4 (4)  
     Grade 2 2 (2)  1 (1)  
     Grade 3a 0 (0)  0 (0) 
 
     Grade 3b 1 (1)  5 (4)  
     Grade 4a 
 
4 (3)  7 (6) 
 
     Grade 4b 
 
0 (0)  0 (0) 
 
     Grade 5 0 (0)  0 (0) 
 
Kidney hematomas, no (%) 3 (2)  1 (1) 0.3 1 
Secondary treatment, no (%) 16 (13)  7 (6) 0.06 1 
     Re-ESWL 10 (8)  1 (1) 
 
     JJ stent 2 (2)  1 (1) 
 
     Percutaneous nephrolithotomy 0 (0)  0 (0) 
 
     Ureterorenoscopy 4 (3)  5 (4) 
 
 
1
 Chi square test                 2 Mann Whitney test 
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Table 3 - Multivariate regression analysis of treatment success in 
relation to treatment parameters, and stone characteristics 
  p value OR (95% CI) 
SW delivery rate 0.02 0.43 (0.19-0.96) 
Stone location 0.008 4.96 (1.69-16.83) 
Stone density 0.0003 0.23 (0.1-0.49) 
Stone size 0.0008 0.62 (0.52-0.77) 
JJ 0.03 0.96 (0.93-0.99) 
Abbreviations: SW = shock wave; JJ = Double-J stent; OR = odds ratio 
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Figure 1  
CONSORT diagram enumerating the patients screened, randomized, allocated to each 
treatment arm, lost to follow up, and included in the final analysis. 
 
 
Figure 2 
Distribution of stone composition. Stone analysis could be obtained in 75/127 (59%) of group 
A patients and 81/113 (72%) of group B patients. 
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Fig. 1 
 
 
       
 
 
 
 
 
 
 
Assessed for eligibility  
(n=260) 
Excluded  (n=6) 
  - Not meeting inclusion criteria (n=0) 
  - Refused to participate (n=2) 
  - Other reasons (n=4 ) 
Analyzed  (n=127) 
  - Excluded from analysis  (n=0) 
Lost to follow-up  (n=3) 
Discontinued intervention (n=0) 
Group A 
Allocated to 60 SWs per min  (n=130) 
  - Received allocated intervention (n=130) 
  - Did not receive allocated intervention (n=0) 
Lost to follow-up  (n=11) 
Discontinued intervention (n=0) 
Group B 
Allocated to 90 SWs per min (n=124) 
  - Received allocated intervention (n=124) 
  - Did not receive allocated intervention (n=0) 
Analyzed  (n=113) 
  - Excluded from analysis  (n=0) 
Allocation 
Follow-Up 
Enrolment 
Randomized 
(n=254) 
Analysis 
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Fig. 2 
Stone composition
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Key of definitions and abbreviations 
ESWL   extracorporeal shock wave lithotripsy 
JJ stent  double J stent 
SW   shock wave 
URS   ureterorenoscopy 
 
 
